Rheumatology Therapeutics Market Size, Share, Trends, Growth and Forecast 2032

According to a report from Zion Market Research, the global Rheumatology Therapeutics Market was valued at USD 35.47 Billion in 2023 and is projected to hit USD 44.29 Billion by 2032, with a compound annual growth rate (CAGR) of 2.5% during the forecast period 2024-2032.

This report explores market strengths, weakness, opportunities, and threats. It also provides valuable insights into the market's growth drivers, challenges, and the future prospects that may emerge in the Rheumatology Therapeutics Market industry over the next decade.

Request Free Sample

Global Rheumatology Therapeutics Market Overview     

Musculoskeletal conditions are a major burden on the individual, society and the healthcare service providers. These conditions result in joint inflammation, pain, swelling, and stiffness. Rheumatic disease is one of the leading causes of morbidity in around the world. People of all ages, genders, and races can have arthritis, and it is the leading cause of disability in the United States. More than 50 Billion adults and almost 300,000 children have arthritis or some other type of rheumatic disease. Rheumatic diseases are generally common among women and occur more frequently as people get older.

Growth Factors

The growing burden of rheumatic diseases around the world is fostering the growth of rheumatology therapeutics market. A wide number of biosimilars and drugs under pipeline are fostering the growth of the market. However, high capital investments in drug development, stringent rules and regulations are slowing the growth of the market. Technologically enhanced products such as biologics and biosimilars are expected to present lucrative business opportunities in future.

Rheumatology Therapeutics Market: Report Scope

Segment Analysis Preview  

On the basis of disease type, the global rheumatology therapeutics market is divided into rheumatoid arthritis, osteoarthritis, lupus, gout, ankylosing spondylitis and other. Rheumatoid arthritis disease has high prevalence rates than other disease and accounts for the major share in global rheumatology therapeutics market.  

On the basis of drug type the market is segmented into non-steroidal anti-inflammatory drugs, analgesics, disease modifying anti-rheumatic drugs, corticosteroids and other. DMARDs segment dominated the market in 2016 owing to their increased in use in the early stage of treatment. The distribution channel segment of rheumatology therapeutics includes a retail pharmacy, online pharmacy, and hospitals.

Request Free Sample

Regional Analysis Preview  

The global rheumatology therapeutics market was dominated by North America and it held a maximum share of total revenue generated in 2020. The growth in this region is attributed to the increased geriatric population and soaring capital investments in the pharma sector. Europe is another leading regional market followed by North America. Growing incidences of rheumatoid diseases and advanced healthcare infrastructure is accounting the growth in this region. The Asia Pacific is the fastest growing market and is expected to show strong growth in the forecast period. The growth in this region is primarily driven due to increasing geriatric population in countries like China and India. Japan is also accounting for a key share in Asia Pacific market owing to the presence of elderly population. Latin America is an emerging market due to rising healthcare infrastructure in this region.

Key Market Players & Competitive Landscape

Some of key players in Rheumatology Therapeutics Market are -

• AbbVie
• Pfizer
• Bristol-Myers Squibb Company
• Merck & Co.
• Amgen
• Janssen Biotech
• Novartis AG
• Genentech
• Takeda Pharmaceutical and Sanofi among others.

Request Free Sample

The global Rheumatology Therapeutics Market is segmented as follows:   

By Disease Type

• Rheumatoid Arthritis
• Ankylosing spondylitis
• Osteoarthritis
• Lupus
• Gout
• Other

By Drug Type

• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)     
• Analgesics  
• Disease Modifying Anti-Rheumatic Drugs (DMARDs)      
• Corticosteroids
• Others

By Distribution Channel

• Retail Pharmacy       
• Online Pharmacy        
• Hospitals       
• Other       

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa